Current and future drug treatments for glioblastomas

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.

Original languageEnglish
Pages (from-to)4309-4316
Number of pages8
JournalCurrent Medicinal Chemistry
Volume23
Issue number38
DOIs
Publication statusPublished - 01-11-2016

Fingerprint

temozolomide
Drug therapy
Glioblastoma
Carmustine
Pharmaceutical Preparations
Therapeutics
Vascular Endothelial Growth Factor A
Tumors
Monoclonal Antibodies
Radiation
Glioma
Immunotherapy
DNA

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

@article{5c67ab3d554f45d8aa90af8e83105929,
title = "Current and future drug treatments for glioblastomas",
abstract = "Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10{\%}. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.",
author = "Shigeo Oba and Yuichi Hirose",
year = "2016",
month = "11",
day = "1",
doi = "10.2174/0929867323666161014132907",
language = "English",
volume = "23",
pages = "4309--4316",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "38",

}

Current and future drug treatments for glioblastomas. / Oba, Shigeo; Hirose, Yuichi.

In: Current Medicinal Chemistry, Vol. 23, No. 38, 01.11.2016, p. 4309-4316.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current and future drug treatments for glioblastomas

AU - Oba, Shigeo

AU - Hirose, Yuichi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.

AB - Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.

UR - http://www.scopus.com/inward/record.url?scp=85006791726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006791726&partnerID=8YFLogxK

U2 - 10.2174/0929867323666161014132907

DO - 10.2174/0929867323666161014132907

M3 - Review article

C2 - 27758718

AN - SCOPUS:85006791726

VL - 23

SP - 4309

EP - 4316

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 38

ER -